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standardized and validated Quality-of-life-instrument, con-
sisting of 36 questions that can be aggregated into 8 health
dimensions. The EuroQol is also a general, standardized
and validated quality-of-life-questionnaire, having the ad-
vantage of aggregating the five health dimensions into one
quality-of-life-index. Therefore, the EuroQol is frequently
used in health economic evaluations to calculate Quality ad-
justed life years saved (QALYs). In the TTO interview pa-
tients are asked questions to calculate a quality-of-life-index
for each patient stratified by age. In the willingness-to-pay-
questionnaire, obese patients are asked how much they
would be prepared to pay per month for an immediate and
sustained weight loss of 10 kg from their current body
weight. The answers are stratified by net income classes.
RESULTS: Quality of life measured by the SF 36 has im-
proved in all 8 health dimensions at visit 2 compared to
visit 1. Especially energy/fatigue is impaired in obese pa-
tients. The quality-of-life-index measured by the EuroQol
has slightly improved from visit 1 to visit 2 over all age-
groups. The quality-of-life-index of the TTO-interview
and the EuroQol-questionnaire are very similar except for
the age group 35 years. Willingness-to-pay correlates
positively with net income.
DISCUSSION: The results are preliminary, but in line with
the published literature. They reveal the massive burden of
obese patients.
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OBJECTIVE: Managing the data collected in multi-country
cost of illness studies is a major task. The objective of this
task is to ensure the accuracy and confidentiality of the data
collected and to provide a flexible platform for analysis.
METHOD: The CODE-2* (Costs of Diabetes in Europe
type 2) study was conducted simultaneously in 8 European
countries to evaluate the total burden of type 2 diabetes.
Resource utilisation, clinical and demographic data were
collected using specifically designed data collection instru-
ments. Over 3 million discrete items of data relating to over
7000 patients were collected and entered, transmitted and
stored within a centralized database. This was achieved us-
ing HTML and XML programming and software technol-
ogy as the basis for data entry and data file creation and
IDT** encryption techniques to ensure data privacy for
data sent via the Internet to a central server database. These
novel systems offer a number of advantages such as: user
friendly data entry screens, on line data validation, ‘limit-
less’ data entry for certain resource items (e.g., practitioner
visits), on line program updates, exception data reports, file
status reports, confidential data transfer, central data vali-
dation, derived variable creation, on line analytics and
progress reports, and data export functionality to analyti-
cal packages such as SAS, SPSS and Excel.
RESULTS: As a result of using this data management ap-
proach, a consistent and high quality data set for analysis
was assured for the CODE-2 study.
CONCLUSIONS: Internet technology, such as that used in
the CODE-2 study, should have a greater role to play in the
collection and management of data in future multi-country
cost of illness studies. *Registered Trademark of SmithKline
Beecham. **Registered Trademark of MDS.
PEN3
DEVELOPMENT OF AN ALGORITHM FOR 
ESTIMATING ASTHMA SEVERITY FROM AN 
ADMINISTRATIVE COST DATABASE
Leidy NK1, Paramore LC1, Watrous M2, Doyle J3, Zeiger RS4
1MEDTAP International, Bethesda, MD, USA; 2Genentech, Inc., 
South San Francisco, CA, USA; 3Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA; 4Kaiser Permanente, San 
Diego, CA, USA
OBJECTIVES: The purpose of this study was to develop
and test an algorithm for estimating disease severity for
economic studies involving administrative cost database
analyses. The intent was to go beyond the traditional
three-group classification (mild, moderate, severe) and de-
velop a more refined four-group system consistent with
NHLBI Guidelines for estimating asthma severity: mild in-
termittent (MI), mild persistent (MP), moderate persistent
(MoP), severe persistent (SP).
METHODS: A retrospective cohort design was used, em-
ploying administrative claims from a fee-for-service pro-
vider of health care benefits to approximately 3.5 million
federal employees in the U.S. Patients with asthma were
defined by: 
1 medical encounters for asthma (exclusive
of COPD and allergic rhinitis) during 1994–5 and continu-
ous enrollment in the health plan for 24 months; 22,833
patients with asthma were identified. Four algorithms
were developed using NHLBI guidelines for pharmaco-
logic intervention with adjustments for practice patterns
during 1994-5. Evaluation was based on the observed se-
verity distribution in the population and results from bi-
variate and multivariate analyses in random samples, ex-
amining the relationship between severity level and the
following clinically-grounded variables: deaths, hospital-
izations, ER visits, and use of an allergist/pulmonologist.
RESULTS: The final algorithm was a 2-step procedure
based on -2 agonist and oral steroid use. Severity distri-
bution in the population was as follows: 69.5% MI,
16.9% MP, 11.1% MoP, and 2.5% SP. The final, popula-
tion-based bivariate analyses showed a logical stair-step
pattern with significant relationships between severity and
death rates, number of hospitalizations, and specialist use
(p  .001). The ordinal logistic regression model was also
significant (p  .0001; chi-square  597.45, df  4), with
a Goodman-Kruskal Gamma statistic of 0.25.
CONCLUSION: Results suggest the algorithm is useful
for classifying patients into four levels of severity using an
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administrative cost database. Clinical validation of the al-
gorithm is warranted.
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OBJECTIVES: The total economic impact of type 2 diabe-
tes in Germany is widely unknown and underestimated
since its complications are often not taken into account.
The pan-European cost of illness study (CODE-2: Costs of
Diabetes in Europe, Type 2) aimed at measuring the total
cost of patients with type 2 diabetes including both costs
of management and complications.
METHODS: For Germany, a bottom-up, prevalence-
based design was used to collect data on resource utilisa-
tion of 809 patients with diabetes type 2 for the year 1998.
A representative random sample of 135 office-based physi-
cians (GPs and specialists) provided data using patients’
medical records in face-to-face interviews. For the extrapo-
lation on a population level, costs were weighted accord-
ing to prevalence data on complications derived from an
epidemiological pre-study. Data were analysed from a so-
cietal perspective.
RESULTS: Total direct medical costs per patient per year
were on average DM 7,012, ranging from DM 156 to DM
137,512. The main part of the costs (61%) was induced
by hospitalisations and long-term care. Observed costs per
treatment type were DM 5,890 for diet, DM 5,621 for
OAD and DM 9,799 for insulin-treated patients. The
analysis per complication status showed a range from DM
3,716 for patients without, and up to DM 13,283 for pa-
tients with both micro- and macrovascular complications.
Assuming a diabetes type 2 prevalence of 4.24%, the total
annual direct costs for the respective population were esti-
mated to be DM 24,388 million.
CONCLUSIONS: The data substantiate the enormous so-
cio-economic burden and that costs are much higher than
estimated in previous studies. Treatment costs of diabetes
show a broad variance. Costs increase with age and are
highly related to occurrence of complications and onset of
insulin treatment. Furthermore, the study highlights that
costs are directly related to the severity of the patient’s ill-
ness.
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OBJECTIVES: Underlying the success of multi-country
cost of illness studies are the methods used to identify, enu-
merate and value the resources that constitute the overall
costs of the disease being studied. The design objective of
the data collection instruments is to ensure consistency be-
tween countries and retrieval of all relevant data.
METHODS: The CODE-2* (Costs of Diabetes in Europe
type 2) study is a bottom-up, prevalence based cost of ill-
ness study conducted to evaluate the total burden of type 2
diabetes in 8 European countries. The objective of the
study was to fully identify all costs relating to the manage-
ment of the disease and its associated complications in ad-
dition to patient demographic and clinical parameters.
Data for over 7000 patients were collected retrospectively
over a 6-month period from a variety of sources including
patient interviews, medical records and registries. This re-
quired the design of common data collection tools that
could be used in all eight countries by over 600 practitio-
ners included in the study. Identification of core items of
resource utilisation and clinical assessments was done in
consultation with European and national advisory boards
consisting of health economists, clinicians and healthcare
researchers. A process of forward and back translation en-
sured the cultural and linguistic integrity of the eight lan-
guage versions used. Layout and instrument design were
developed by iteration between the central study coordi-
nating and country teams and assessed by mini-pilots. Fi-
nal field tests ensured acceptability and suitability for
study participants.
RESULTS: The resulting country specific practitioner and
patient data collection instruments were consistent in all
aspects for core resource utilisation items necessary for in-
ter-country comparison of the study results.
CONCLUSION: The instruments and development pro-
cess used for the CODE-2 study should serve as a model
for other multi-country cost of illness studies. *Registered
Trademark of SmithKline Beecham
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OBJECTIVES: To estimate for the United Kingdom (UK)
and France the first year diabetes-related costs of naive pa-
tients with type 2 diabetes initiated upon therapy with the
same oral hypoglycemic agent (Diamicron). In both the
UK and France, responsibility for the care of patients with
type 2 diabetes rests with general practitioner physicians.
METHODS: Patient records of consecutive naive patients
were collected from general practices (two in the UK, one in
France). Diabetes-related resource utilization and costs for
the first year post-initiation of oral therapy were analyzed.
This included medication, professional visits, hospital out-
patient visits, emergency visits, inpatient hospitalizations,
laboratory tests and procedures, and self-administered tests.
